The prices in the Chinese medical beauty industry are gradually decreasing, with the price of a vial of childlike beauty injections dropping from 20,000 yuan to 999 yuan. At the same time, the financial performance of multiple medical beauty companies has also shown a decline. Some industry insiders believe that the price war in the medical beauty industry is far from over.
According to a report from “Leopard Change,” a subsidiary of Jingzhuyan Information Technology Co., Ltd., Ms. Li Jin from Beijing recently noticed a change at her local beauty salon. While waiting for her beauty treatment, the salon no longer provided customers with health tea but instead offered bottled water.
Li Jin revealed that since July 2025, there has been a noticeable drop in prices for medical beauty treatments. A cosmetic procedure that cost 30,000 yuan in 2024 only costs 9,800 yuan during the same period in 2025.
Experienced medical beauty consumers have noted a widespread decrease in prices for beauty treatments. For instance, a vial of childlike beauty injections that cost nearly 20,000 yuan in 2024 can now be purchased for 6,400 yuan, and during promotional periods, it can even be bought for 999 yuan through group discounts.
The report indicates that medical beauty institutions are actively seeking price reductions to attract more clients. As a result, consumers’ expectations for medical beauty prices are decreasing, leading to a spiral decline in prices in the industry.
Moreover, people are beginning to spend less money on beauty treatments. According to the “China Medical Beauty Industry 2025 Insight Report” jointly released by Deloitte and the Chinese Association of Aesthetic Plastic Surgery, middle to high-income individuals are becoming more conservative in their spending on medical beauty. In 2024, 78% of medical beauty consumers maintained or increased their spending, but in 2025, this figure dropped to 57%.
As medical beauty prices continue to fall, related companies are experiencing a decline in revenue. Companies like Huaxi Biotech and Aimeike, once known as the “Maotai of medical beauty” for their high market value and strong profitability, seem to be losing their favor in the capital market. In 2025, Huaxi Biotech saw a 21.82% year-on-year decline in revenue, while Aimeike’s revenue and net profit dropped by 18.84% and 34.05%, respectively.
Huaxi Biotech attributed its declining performance to the impact of industry price competition, which put pressure on product sales.
Some industry insiders have told the media that seeing the profitability of the medical beauty industry, many companies are investing in this sector, leading to intensified competition, and the price war shows no signs of stopping.
Internet users are surprised by the significant drop in beauty treatment prices. User “The World is Big” said, “How can the price of childlike beauty injections drop so much?”
User “Yuan Bao” stated, “The effectiveness of childlike beauty injections varies from person to person, depending on skin condition and the doctor’s technique. The drastic price drop from 20,000 to 1,000 yuan may indicate a significant gap between product value and price.”
User “I Think I Am the Sea” believes, “The cost is only a few dozen yuan at most. When it’s hyped up to such a high price, it shows that the economy is in trouble, and it’s naturally becoming more difficult to deceive people.”